1Pernefri Indonesia, Bandung, Indonesia
Aim: The objective of this study is to associate between sclerostin and calcium and organic phosphorus levels in predialytic chronic kidney disease patients
Background: Sclerostin is a 190-amino-glycoprotein plays a role in decreasing bone formation by inhibiting osteoblastic differentiation through Wnt signaling pathways and enhancing apoptosis. In patients with chronic kidney disease (CKD), sclerostin is a biomarker Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) and contributors to cardiovascular disease, through increased vascular calcification.
Method: This is a cross-sectional design using secondary data of previous sclerostin linkage to vascular calcification study.
Result: The results showed that mean levels of calcium and organic phosphorus between stage 3, 4, and 5 CKD, consecutively were 8.71, 8.74 and 8.24 (significantly different, p = 0.027) for calcium and 3.42, 3.47 and 4.08 (significantly different, p = 0.006) for organic phosphorus. There were no significant difference of CaP product among patients with stage 3,4, and 5 of CKD (p> 0,05). There was significant correlation between calcium and sclerostin (r = 0.254; p <0.05), however, there were no significant correlation between phosphorus and sclerostin (r = 0.069; p = 0.274) and between CaP product and sclerostin (r = 0.170; p = 0.068 ).
Conclusion: There is a positive correlation between calcium levels and sclerostin and the decline in kidney function affects bone mineral homeostasis.
Dr. Dede Satia Sukmana. Born in Garut City, Indonesia, December, 25th, 1966. General doctor graduated in 1991 and Internal medicine graduated in 2004 from Medical Faculty Padjadjaran University Bandung Indonesia. Now traine nephrologist at the Medical Faculty Padjadjaran University and working as staff at the Naval Hospital Tanjungpinang Indonesia.